clinical trial · NCT07767513
Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events
Shandong Suncadia Medicine Co., Ltd.·phase2·not yet recruiting·n = 60
Lipoprotein DisorderHRS-5346HRS-5346
brief summary
This study is designed to evaluate the efficacy and safety of HRS-5346 Tablets in participants with high cardiovascular event risk and elevated Lp(a), and to investigate the appropriate dosage of HRS-5346 Tablets
started
Sep 1, 2026
primary completion
Feb 1, 2027
completion
May 1, 2027
last updated
Aug 17, 2026
official title
A Randomized, Double-Blind Phase II Study to Evaluate the Efficacy and Safety of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol